Index

ABPM. See ambulatory blood pressure monitoring
ACCF/AHA. See American College of Cardiology Foundation/American Heart Association
ACEP. See American College of Emergency Physicians
Ad Hoc Syncope Consortium, 177–78
adenosine triphosphate (ATP) test, 160
alcohol, 68, 70, 103, 112, 113, 130. See also intoxications, syncope
alpha blockers, 130
ambulatory blood pressure monitoring (ABPM), 56–60
syncope and, 56–60
neurally-mediated reflex, 57–58
TLOC and, 56–60
ambulatory cardiac monitoring, syncope and, 51–55
American Autonomic Society, 177
American College of Cardiology Foundation/American Heart Association
syncope definition by, 7
Syncope Statement, deficiencies in, 177–79, 182
Ad Hoc Syncope Consortium and, 177–78
Heart.org and, 177
American College of Emergency Physicians (ACEP), 26, 141, 146
antidepressants, tricyclic, 130
arrhythmias. See bradyarrhythmias; tachyarrhythmias; ventricular arrhythmias
arrhythmic syncope, pathophysiology of, 15, 17–18
arrhythmogenic right ventricular dysplasia (ARVD), 25, 63, 64, 91–92, 93, 112, 113
ARVD. See arrhythmogenic right ventricular dysplasia
athletes, with syncope, 135–39
HUTs and, 136–37
ILRs and, 137–38
ATP test. See adenosine triphosphate test
atrial fibrillation, 17, 97, 99, 142
atrioventricular (AV) block, 61, 62, 65, 76, 77, 78, 115, 117, 121, 126, 142
autonomic assessment tests, for syncope, 39–43
autonomic failure
causes of, 67
cerebral perfusion in, 21–22
clinical features, 67–68
in elderly, 123
orthostatic hypotension and, 67, 68
laboratory investigation, 68–69
POTS v., 68
autoregulation, 21, 22
AV block. See atrioventricular block
beta blockers, 130
bifascicular bundle branch block, 76–77
EP testing and, 77–78
syncope and, 76–79
blackouts, xiii, 102
rapid-access blackout clinics and, 106–9, 171, 172, 174
TLOC as, 102, 103, 105, 106, 107, 108
blood pressure (BP), 67, 68, 69, 70
ILR and, 59, 60
BP. See blood pressure
bradyarrhythmias, 61–62
in children/adolescents, 113, 114
bromocriptine, 130
Brugada syndrome, 25, 63, 64, 65, 96–99, 163, 165
ECG recordings and, 96, 97, 98
Calgary Syncope Symptom Study, 46–48
cardiac arrhythmias, 12, 17, 18, 44, 46, 51, 54, 111
cardiac output (CO), 16, 17
cardiac pacing, 87, 163, 166
cardiac syncope, 11, 12, 17, 24, 26, 32
cardiomyopathy
ARVD, 25, 63, 64, 91–92, 112
in children/adolescents, 112, 113
clinical features, 32
generalized approach to, 64, 65
cardiovascular conditions and, 24–25, 26, 61
in children/adolescents, 112, 113
clinical features, 32
care pathways, for syncope, 173
carotid sinus hypersensitivity (CSH), 121, 122, 124, 126, 127
carotid sinus massage (CSM), 42, 122, 125, 126, 127, 136
carotid sinus syndrome (CSS), 86, 87, 120, 121, 122, 125, 126, 127
catatexy, 12, 33, 34, 45, 178
catecholamine determinations, 42
catecholaminergic polymorphic ventricular tachycardia, 95, 100, 114
CBF. See cerebral blood flow
cerebral blood flow (CBF), 20, 21, 22
MAP and, 20, 21
cerebral hypoperfusion, global, 5, 15
cerebral perfusion, 20–21
in autonomic failure, 21–22
in syncope, 20–23
neurally-mediated, 21
cerebrovascular syncope, 32
channelopathies, syncope and, 95–101
children/adolescents
bradyarrhythmias in, 113, 114
hypertrophic cardiomyopathy in, 112, 113
long QT syndrome in, 103, 104, 114
short QT syndrome in, 114
SVIs in, 112, 113
syncope in, 111–18
cardiac, 112, 113, 114
causes of, 113
inherited syndromes and, 114
neurally-mediated/vasovagal, 113, 166
pseudo, 113
tachyarrhythmias in, 113
TLOC in, 111–18
ventricular arrhythmias in, 113, 114
clinical epidemiology, of syncope, 11–12
clinical trials, syncope management and, 157–68
clinics, syncope, 109. See also rapid-access blackouts clinics
multidisciplinary, 171
CO. See cardiac output
collapses, 102, 103. See also falls
ambulance crew responses to, 108
EDs’ response to, 106, 108
physician/family response to, 107, 108
coma, syncope v., 4, 5, 6
conclusions, syncope v., xiii, 4, 5, 6, 178
conduction tissue disease, 121, 124
convulsive syncope, 103. See also epilepsy; seizures
coronary artery disease, syncope and, 90
cough syncope, 12, 22
CSH. See carotid sinus hypersensitivity
CSM. See carotid sinus massage
CSS. See carotid sinus syndrome

DEFINITE. See Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation
dementia, 120, 122
diagnostic algorithm, for syncope, 173
disease, vasovagal syncope as, 166
diuretics, 92, 120, 130
driving restrictions, syncope and, 153–55
ICDs in, 153, 154, 156
drug therapy
for NMS/vasovagal syncope, 84–85
failure of, 157–58
for orthostatic hypotension, 70
QT interval and, 131
drug-induced syncope, 129–32. See also intoxications, syncope v.
dysautonomia, 56
dysplasia. See arrhythmogenic right ventricular dysplasia; cardiomyopathy
ECGs. See electrocardiograms
echocardiograms, 61, 64, 65, 76, 116, 135, 136, 142, 171
EDs. See emergency departments
EEGs. See electroencephalograms
EGSYS. See Evaluation of Guidelines in Syncope Study
elderly
autonomic failure in, 123
collapses, 103, 119–28
syncope in, 12, 33, 119–28
causes of, 121–24
clinical features, 124–25
epidemiology, 120
ESC guidelines and, 49
investigations, 125–27
pathophysiology, 120–21
vasovagal, 53, 121, 122, 166
TLOC in, 119–28
electrocardiograms (ECGs), 25, 26, 36, 48, 57, 64, 65, 103
Brugada syndrome and, 96, 97, 98
long QT syndrome and, 95–96, 103, 104
monitoring systems, new, 160–61
short QT syndrome and, 99
sleep syncope and, 32–33
syncope and long-term, 58, 59
electroencephalograms (EEGs), 20
epilepsy and, 104
sleep syncope and, 32–33
in tilt-induced syncope, 20
electrophysiologic (EP) testing, 25, 61–66
athletes and, 137
bifascicular bundle branch block and, 77–78
ICDs and, 62
indications for, 93
Index

emergency departments (EDs) response to collapses by, 106, 108
SEEDS and, 141, 142, 146, 161
syncope evaluation in, 36–38, 169
syncope management units in, 140, 141–43
EP testing. See electrophysiologic testing epidemiologic aspects, of TLOC/syncope, 8–14
in elderly, 120
future research, 13
epilepsy. See also seizures EEGs and, 104
syncope v., xii, xiii, 4, 5, 6, 12–13, 44, 102–10, 170
during sleep, 32, 33
EPS. See electrophysiologic testing ESC. See European Society of Cardiology etilefrine, 85
European Society of Cardiology (ESC) syncope guidelines, xiii, 4, 5, 6, 31, 32, 78, 176–77
elderly and, 49
rapid-access blackouts clinics and, 109
Task Force on Syncope, 40, 141
Evaluation of Guidelines in Syncope Study (EGSYS), 143, 144, 146, 179, 180
exercise testing, 100, 136, 137. See also athletes, with syncope
external loop recorders, 52
fainting. See syncope falls, 68, 103, 105, 106, 107, 108, 109. See also collapses in elderly, 103, 119–28
syncope v., 119–20, 170
females, syncope and, 10
fludrocortisone, 47, 69, 70, 85, 131, 157, 158, 163, 164
flying restrictions, syncope and, 153, 155–56
ICDs in, 153, 154, 156
Framingham study, 9, 24
head-up tilt tests (HUTs), 40, 56, 57
athletes and, 136–37
effectiveness of, 160
vasovagal syncope and, 40, 57
health-related quality of life (HRQL) study, syncope and, 149
heart disease (structural), syncope and, 89–94, 104, 165
heart rate (HR), 67, 68, 69
Heart Rhythm Society (HRS), 141, 146
guidelines, 155, 177
Heart.org, 177
criticisms of ACCF/AHA statement on, 177
His-Purkinje system dysfunction, 61, 62, 78
history. See medical history, syncope and Holter monitoring, 51–52
hospitals, syncope management units in, 143–46
HRQL study. See health-related quality of life study
HRS. See Heart Rhythm Society
HUTs. See head-up tilt tests
hypertrophic cardiomyopathy, 17, 25, 63, 64, 65, 91, 92, 93, 95, 112
in children/adolescents, 113, 114
hypotension. See orthostatic hypotension; postprandial hypotension
iatrogenic syncope, 129–32
ICDs. See implantable cardioverter-defibrillators
ILRs. See implantable loop recorders
impedance threshold device (ITD), 15
implantable cardioverter-defibrillators (ICDs), 25, 103, 104, 154
clinical trials for, 163, 165
driving/flying restrictions and, 153, 154, 156
indications for, 93
patient selection for, 89–94
syncope and, 25–26, 53, 54, 78
tachyarrhythmias and, 62, 63
implantable loop recorders (ILRs), 13, 17, 45, 52–53, 59, 78, 104, 105
athletes and, 137–38
blood pressure and, 59, 60
EP testing and, 62
NMS/vasovagal syncope and, 160
tilt-table testing and, 48–49
inappropriate sinus tachycardia (IST), 39, 40
inherited syndromes
clinical trials and, 163–65
syncope in children/adolescents and, 114
insulin, 130
International Study on Syncope of Uncertain Etiology (ISSUE), 53, 77, 85, 86, 160, 164, 179
intoxications, syncope v., xiii, 4, 6
ischemic cardiomyopathy, 62–63, 64
ISSUE. See International Study on Syncope of Uncertain Etiology
IST. See inappropriate sinus tachycardia
ITD. See impedance threshold device
joint hypermobility system, 68, 69
laughter-induced syncope, 31, 33–34
long QT syndrome (LQTS), 25, 63, 64, 65, 95–96, 112, 163, 165
in children/adolescents, 103, 104, 114
ECGs and, 95–96, 103, 104
observational trial, 163, 165
Index

loop recorders. See external loop recorders; implantable loop recorders
LQTS. See long QT syndrome
MADIT. See Multicenter Automatic Defibrillator Implantation Trial
MAP. See mean arterial pressure
MCOT system. See mobile cardiac outpatient system
mean arterial pressure (MAP), 20
CBF and, 20, 21
medical history, syncope and, 31–35, 115–16
TLOC in, 31, 34
metoprolol, 157, 158
midodrine, 69, 70, 85, 86, 127, 131, 163, 164
mobile cardiac outpatient telemetry (MCOT) system, 52, 138, 161
monoamine oxidase inhibitors, 70, 130
mortality, syncope and, 24, 25, 26
MSA. See multiple system atrophy
Multicenter Automatic Defibrillator Implantation Trial (MADIT), 63
multidisciplinary management of syncope/TLOC, 169–75
multinational syncope/TLOC guidelines, xiv, 179–81
syncope clinics, 171
multiple system atrophy (MSA), 39, 40, 67, 123
narcolepsy, 12, 34, 45
narcotics, 130
neurally-mediated syncope (NMS), 16–17
approach to, 44–45
autonomic assessment, 40, 41
Calgary Syncope Symptom Study and, 46–48
cerebral perfusion in, 21
in children/adolescents, 113, 166
clinical epidemiology of, 11, 12, 13
clinical features, 32
clinical trials for, 165–66
as disease, 166
drug therapy for, 84–85
failure of, 157–58
in elderly, 33, 121, 122, 166
falls v., 119–20, 170
HUT and, 40, 57
ILRs and, 160
occurrence/frequency of, 102, 112
pacemakers and, 85–86
pathophysiology of, 15, 16–17
physical maneuvers for, 83–84, 158–59
quantitative histories and, 45–46
risk stratification, 48
starting of, 10
treatment strategies for, 83–88, 86
nitrates, 130
NMS. See neurally-mediated syncope
nonischemic cardiomyopathy, 63, 64
syncope and, 90–91
noradrenaline transporter system, 68
norepinephrine levels, 42
OESIL. See Osservatorio Epidemiologico della Sincope nel Lazio
OH. See orthostatic hypotension
orthostatic hypotension (OH), 39–40, 56
autonomic failure and, 67, 68
laboratory investigation, 68–69
treatment strategies, 69
definition of, 40
management of, 69, 70, 71
drug therapy and, 70
nonpharmacologic measures, 70
physical maneuvers for, 72–73
POTS and, 69
syncope and, 11, 12, 15, 16, 17, 18, 40
clinical features, 32
Osservatorio Epidemiologico della Sincope nel Lazio (OESIL), 26, 48, 144, 179
pacemakers, 76, 78
vasovagal syncope and, 85–86
pacing, cardiac, 87, 163, 166
PAF. See pure autonomic failure
pathophysiology, of syncope, 15–19
arrhythmic, 15, 17–18
in elderly, 120–21
neurally-mediated/vasovagal, 15, 16–17
postural, 15–16
PCM trial. See Physical Counterpressure Maneuvers trial
phenothiazines, 130
Physical Counterpressure Maneuvers (PCM) trial, 83, 158
physical maneuvers, 72–73, 83–84, 158–59
effectiveness of, 158–59
NMS/vasovagal syncope and, 83–84, 158–59
for orthostatic hypotension, 72–73
physiology, of upright posture, 15–16
PI. See pulsatility index
POST. See Prevention of Syncope Trial
postprandial hypotension (PPH), 58, 59, 60, 70, 113, 120, 126
postural orthostatic tachycardia syndrome (POTS), 39–40, 67
autonomic failure v., 68
orthostatic hypotension and, 69
postural syncope, pathophysiology of, 15–16
posture. See upright posture
POTS. See postural orthostatic tachycardia syndrome
PPH. See postprandial hypotension
Prevention of Syncope Trial (POST), 47, 87, 157, 164
pseudo syncope, 11, 12, 49, 102, 103, 163, 178
in children/adolescents, 113
pseudo TLOC, 5
pulsatility index (PI), 21
pure autonomic failure (PAF), 39, 40, 42, 67, 123
pyridostigmine, 69, 70
QOL. See quality of life
QT-interval syndrome, 25, 63, 64, 65
long, 25, 63, 64, 65, 95–96
in children/adolescents, 103, 104, 114
observational trial, 163, 165
short, 25, 63, 64, 65, 95, 99
in children/adolescents, 114
quality of life (QOL), syncope/TLOC and, 148–49
randomized clinical trials (RCTs), 158, 180.
See also clinical trials, syncope management and
rapid onset, 4
rapid-access blackouts clinics, 106–9, 171, 172, 174
ESC guidelines and, 109
objectives of, 108
operation of, 108, 109
patient flow through, 109
RCTs. See randomized clinical trials
risk stratification, of syncope, 24–28, 142
EDs and, 36–38
hospital admission and, 141
neurally-mediated reflex, 48
new approaches to, 26
ROSE trial, 26
SAFE PACE study, 122, 179
salt, 157, 158
San Francisco Syncope Rule, 26, 48, 162, 164
SCD-HeFT. See Sudden Cardiac Death in Heart Failure Trial
SCN5A gene, 99
sedatives, 130
SEEDS. See Syncope Evaluation in the Emergency Department Study
seizures. See also epilepsy
disorder, 32, 45, 102
in syncope, 102, 103
self-limited symptom, 4–5
short QT-interval syndrome, 25, 63, 64, 65, 95, 99
in children/adolescents, 114
ECG recordings and, 99
sick sinus syndrome (SSS), 114, 117, 121, 124
Sickness Impact Profile (SIP), 148
sildenafil, 130
SIP. See Sickness Impact Profile
situational syncope, 113, 153, 171
sleep syncope, 31–33
ECGs and, 32–33
EEGs and, 32–33
Standing Test, 39–40, 56
Stokes-Adams attack, 17
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 25, 63, 91, 154
sudden death, syncope v., 5, 6, 24, 89–90, 92, 100
supraventricular tachycardias (SVTs), 17, 25, 47, 77, 78, 90, 97, 112, 114, 123
in children/adolescents, 112, 113
SVTs. See supraventricular tachycardias
sympathomimetics, 69, 70, 130
symptom, 3
self-limited, 4–5
Symptom Checklist 90, 148
syncope. See also cardiac syncope; neurally-mediated syncope; vasovagal syncope
ABPM and, 56–60
ages for start of, 10
ambulatory cardiac monitoring and, 51–55
arrhythmic, pathophysiology of, 15, 17–18
athletes with, 135–39
autonomic assessment tests for, 39–43
bifascicular bundle branch block and, 76–79
causes of, 20, 22, 112
channelopathies as, 95–101
compilation of, 170
in elderly, 121–24
and CBF; diminished, 20, 22
cerebral perfusion in, 20–23
cerebrovascular, 32
in children/adolescents, 111–18
clinical epidemiology of, 11–12
clinics, 109
multidisciplinary, 171
coma v., 4, 5, 6
community prevalence of, 9–10, 13
conussions v., xiii, 4, 5, 6, 178
convulsive, 103
coronary artery disease and, 90
cough, 12, 22
definition/classification of, 3–7, 15, 61, 111, 112
American College of Cardiology/American Heart Association, 7
diagnostic algorithm for, 173
driving restrictions and, 153–55
drug-induced, 129–32
ECGs and, long-term, 58, 59

in elderly, 12, 33, 119–28
causes of, 121–24
clinical features, 124–25
epidemiology, 120
ESC guidelines and, 49
investigations, 125–27
pathophysiology, 120–21
epidemiologic aspects of TLOC and, 8–14
in elderly, 120
future research, 13
epilepsy v., xii, xiii, 4, 5, 6, 12–13, 44, 102–10, 170
during sleep, 32, 33
evaluation of, 26
approach to, 116–17
diagnostic tests in, 115–16
EDs and, 36–38, 169
physical exam in, 116
falls v., 119–20, 170
females and, 10
flying restrictions and, 153, 155–56
guidelines, xiii, xiv
ESC, xiii, 5, 6, 31, 32, 49, 78, 176–77
initiative, 176–83
multinational/multidisciplinary TLOC/, xiv, 179–81
heart disease (structural) and, 89–94, 104, 165
HRQL study and, 149
iatrogenic, 12–132
ICDs and, 25–26, 53, 54, 78
intoxications v., xiii, 4, 6
laughter-induced, 31, 33–34
management of, xiii
care pathways in, 173
clinical trials and, 157–68
multidisciplinary, 169–75
studies and, xiii–xiv
uniform standard for, xiii, 3, 163
management units, 140–47
in EDs, 140, 141–43
effectiveness of, 161–63
in hospital, 143–46
medical history and, 31–35, 115–16
mortality in, 24, 25, 26
multidisciplinary management of, 169–75
natural history of, 13
nonischemic cardiomyopathy and, 90–91
orthostatic hypotension and, 11, 12, 15, 16, 17, 18, 40
clinical features, 32
pacemakers and, 85–86
pathophysiology of, 15–19
postural, pathophysiology of, 15–16
presenting for care and, 10–11
pseudo, 11, 12, 49, 102, 103, 163, 178
in children/adolescents, 113
QOL and, 148–49
risk stratification, 24–28, 142
EDs and, 36–38
hospital admission and, 141
neurally-mediated reflex, 48
new approaches to, 26
seizures in, 102
situational, 113, 153, 171
sleep, 31–33
ECGs/EEGs and, 32–33
sudden death v., 5, 6, 24, 89–90, 92, 100
tilt-induced, 17, 18
EEG in, 20
finger blood pressure recordings during, 17, 18
TLOC v., 3–7, 102
medical history and, 31, 34
Syncope Evaluation in the Emergency Department Study (SEEDS), 141, 142, 146, 161
tachyarrhythmias, 17, 62–63, 112
in children/adolescents, 113
ICDs and, 62, 63
tachycardias. See inappropriate sinus tachycardia; postural orthostatic tachycardia syndrome; supraventricular tachycardias; ventricular tachycardias
TCDs. See transcranial Doppler devices
tilt training, 72, 73–74, 84
effectiveness of, 158, 159
tilt-induced syncope, 17, 18
EEG in, 20
finger blood pressure recordings during, 17, 18
tilt-table testing, 13, 16, 17, 32, 33, 34, 47, 73–74
ILRs and, 48–49
TLOC. See transient loss of consciousness
torsade de pointes, 95, 96, 130, 131, 132
transcranial Doppler devices (TCDs), 20
transient loss of consciousness (TLOC), xiii, 102, 103, 105, 106, 107, 108
ABPM and, 56–60
blackouts as, 102, 103, 105, 106, 107, 108
causes of, xiii, 6, 7, 112, 169
schematic for, 178
in children/adolescents, 111–18
definition/classification of, 3–7, 111, 112
in elderly, 119–28
epidemiologic aspects of syncope and, 8–14
in elderly, 120
future research, 13
management of, multidisciplinary, 169–75
pseudo, 5
Index

transient loss of consciousness (cont.)
  QOL and, 148–49
  syncope guidelines,
    multinational/multidisciplinary, xiv, 179–81
  syncope v., 3–7, 102
  medical history and, 31, 34
  tricyclic antidepressants, 130

upright posture
  improving tolerance to, 72–75
  physiology of, 15–16

Valsalva maneuver, 69
Valsalva-like maneuver, 22, 34, 69, 120, 126
VASIS. See Vasovagal Syncope International Study
vasodilators, 92, 130
vasovagal syncope, 16–17
  ABPM and, 57–58
  approach to, 44–45
  autonomic assessment, 40, 41
  Calgary Syncope Symptom Study and, 46–48
  cerebral perfusion in, 21
  in children/adolescents, 113, 166
  clinical epidemiology of, 11, 12, 13
  clinical features, 32
  clinical trials for, 165–66
  as disease, 166
  drug therapy for, 84–85
  failure of, 157–58
  in elderly, 33, 121, 122, 166
  falls v., 119–20, 170
  HUT and, 40, 57
  ILRs and, 160
  occurrence/frequency of, 102, 112
  pacemakers and, 85–86
  pathophysiology of, 15, 16–17
  physical maneuvers for, 83–84, 158–59
  quantitative histories and, 45–46
  risk stratification, 48
  starting of, 10
  treatment strategies for, 83–88, 86
  Vasovagal Syncope International Study (VASIS), 85, 179
  ventricular arrhythmias, 37, 49, 53, 77, 78, 89, 90, 91, 92, 93, 95, 98, 100
    in children/adolescents, 113, 114
  ventricular tachycardias (VTs), 17, 112
    catecholaminergic polymorphic, 95, 100, 114
  vincristine, 130
  VT. See ventricular tachycardias

Wolff-Parkinson-White (WPW) syndrome, 104, 113, 114, 117
WPW syndrome. See Wolff-Parkinson-White syndrome